Vivani Medical (VANI) Corporate presentation summary

Market opportunity and challenges

• Obesity market is rapidly evolving, with over 50 clinical-stage products, but all are injectables or orals; a subdermal implant offers a unique, infrequent dosing alternative.

• Poor medication adherence (<50%) and dose fluctuations with current therapies lead to suboptimal outcomes and rapid weight rebound.

• GLP-1 market projected to reach $190B by 2035, with obesity-only TAM at $150B; current U.S. patient penetration is about 6%.

Technology and product pipeline

• NanoPortal technology enables ultra long-acting, miniature drug implants with tunable, near-constant release profiles.

• Lead program NPM-139 is a subdermal semaglutide implant for chronic weight management, with dosing intervals of 6-12 months or longer.

• Pipeline includes next-generation incretin implants and exenatide-based products for obesity, diabetes, and veterinary use.

Clinical and preclinical results

• LIBERATE-1 first-in-human study met primary objectives: positive safety, tolerability, and device performance.

• Preclinical studies show durable weight loss (up to -20% for a year) and 82% liver fat reduction in obese animal models.

• Prototype NPM-139 implant demonstrated sustained semaglutide delivery and weight loss for a full year in rats.